AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17264716 — intervention group
Group type: COMPARATOR
Intervention: Tubes warmed in saline
Number of subjects: 0
Study 17264716 — intervention group
Group type: COMPARATOR
Intervention: Tubes at room temperature (control)
Number of subjects: 0
Study 15084215 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐lead simultaneous ECG (12‐SIM)
Number of subjects: 10
Study 15084215 — intervention group
Group type: EXPERIMENTAL
Intervention: lead II ECG (LEAD II)
Number of subjects: 10
Study 15084215 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐LEAD ECG
Number of subjects: 10
Study 15084215 — intervention group
Group type: EXPERIMENTAL
Intervention: computer‐based, proprietary algorithm, 12SL trade mark ECG Analysis software (AUT)
Number of subjects: 10
Study 11792769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate-buffered peritoneal dialysis (TBL; 25 mM/15 mM bicarbonate/lactate, pH 7.3)
Number of subjects: 10
Study 11792769 — intervention group
Group type: COMPARATOR
Intervention: Lactate-buffered peritoneal dialysis (LPD; 40 mM lactate, pH 5.2)
Number of subjects: 10
Study 11792769 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TBL and LPD at 6 months
Number of subjects: 10
Study 10023500 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI plus inositol
Number of subjects: 27
Study 10023500 — intervention group
Group type: COMPARATOR
Intervention: SSRI plus placebo
Number of subjects: 27
Study 7594424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensives
Number of subjects: 94
Study 7594424 — intervention group
Group type: COMPARATOR
Intervention: Normotensives
Number of subjects: 94
Study 1724914 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 50 micrograms/d
Number of subjects: 204
Study 1724914 — intervention group
Group type: EXPERIMENTAL
Intervention: (T4 50 micrograms/d + T3 12.5 micrograms) x 2
Number of subjects: 204
Study 1724914 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 150 micrograms + iodide 150 micrograms/d
Number of subjects: 204
Study 1724914 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 75 micrograms + T3 18.75 micrograms/d
Number of subjects: 204
Study 1724914 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 200 micrograms/d
Number of subjects: 204
Study 1724914 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 37.5 micrograms/d
Number of subjects: 204
Study 1724914 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodide 300 micrograms/d
Number of subjects: 204
Study 1724914 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 150 micrograms/d
Number of subjects: 204
Study 1724914 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodide 150 micrograms/d
Number of subjects: 204
Study 1724914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 7398983 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of hair lotions with 17 alpha-estradiol (0.025%)
Number of subjects: 51
Study 7398983 — intervention group
Group type: COMPARATOR
Intervention: Control group (hair lotions without 17 alpha-estradiol)
Number of subjects: 51
Study 6833654 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg/day
Number of subjects: 21
Study 6833654 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 270 mg/day
Number of subjects: 21
Study 6833654 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 21
Study 29523624 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 1420
Study 29523624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1420
Study 26463318 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM-201 (600 mg dose in capsules and tablets)
Number of subjects: 30
Study 26463318 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM-201 (600 mg twice daily in capsules)
Number of subjects: 30
Study 24890573 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification (ABM)
Number of subjects: 0
Study 24890573 — intervention group
Group type: COMPARATOR
Intervention: Control (no ABM)
Number of subjects: 0
Study 23135530 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine 0.05% (group A)
Number of subjects: 70
Study 23135530 — intervention group
Group type: COMPARATOR
Intervention: 0.5% carboxymethylcellulose (control; group B)
Number of subjects: 70
Study 20813689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymatrine (150 mg daily, intravenously)
Number of subjects: 80
Study 20813689 — intervention group
Group type: COMPARATOR
Intervention: Gluthion (1.2 g daily, intravenously)
Number of subjects: 80
Study 18445355 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for weight loss (5% to 10% of initial body weight)
Number of subjects: 0
Study 15144909 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative case management intervention
Number of subjects: 246
Study 15144909 — intervention group
Group type: COMPARATOR
Intervention: Usual care with educational materials
Number of subjects: 246
Study 11527895 — intervention group
Group type: EXPERIMENTAL
Intervention: One embryo transfer
Number of subjects: 144
Study 11527895 — intervention group
Group type: COMPARATOR
Intervention: Two embryo transfer
Number of subjects: 144
Study 9523481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood and 3 days of age samples from healthy infants
Number of subjects: 0
Study 9523481 — intervention group
Group type: COMPARATOR
Intervention: Normal children (7 to 17 years)
Number of subjects: 0
Study 8201768 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup at 3 mg/kg
Number of subjects: 64
Study 8201768 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup at 5 mg/kg
Number of subjects: 64
Study 8201768 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup at 10 mg/kg
Number of subjects: 64
Study 8201768 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup at 15 mg/kg
Number of subjects: 64
Study 8201768 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup (overall clinical efficacy)
Number of subjects: 64
Study 8201768 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup at daily doses of 12 - < 18 mg/kg
Number of subjects: 64
Study 8201768 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup at daily doses of 18 - < 27 mg/kg
Number of subjects: 64
Study 8201768 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup at daily doses of 27 - < 33 mg/kg
Number of subjects: 64
Study 8201768 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup (bacteriological eradication)
Number of subjects: 64
Study 2883952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray of LHRH, 0.4 mg thrice daily during 28 consecutive days
Number of subjects: 93
Study 2883952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray of LHRH, 0.4 mg twice daily on alternate days for 1 month
Number of subjects: 93
Study 2883952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray of LHRH, 0.4 mg twice daily on alternate days for 3 months
Number of subjects: 93
Study 29731444 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP 200mg
Number of subjects: 6
Study 29731444 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP 400mg
Number of subjects: 6
Study 29731444 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP 400mg + Metformin 600mg (DT1)
Number of subjects: 6
Study 29731444 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP 400mg (DT2)
Number of subjects: 6
Study 29731444 — intervention group
Group type: COMPARATOR
Intervention: Metformin 600mg (PC)
Number of subjects: 6
Study 26434382 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel group (3 mL 2% lidocaine gel applied to the cervix and intrauterine infusion of 5 mL normal saline)
Number of subjects: 120
Study 26434382 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion group (3 mL gel lubricant applied to the cervix and intrauterine infusion of 5 mL 2% lidocaine)
Number of subjects: 120
Study 26434382 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (3 mL gel lubricant applied to the cervix and intrauterine infusion of 5 mL normal saline)
Number of subjects: 120
Study 25034216 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous initiation of insulin pump therapy (Medtronic Veo©) and continuous glucose monitoring (CGM) (Enlite©)
Number of subjects: 144
Study 25034216 — intervention group
Group type: COMPARATOR
Intervention: Standard pump therapy with delayed CGM introduction
Number of subjects: 144
Study 22253393 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 210
Study 22253393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 20178056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified multimodal work-related programme following a cognitive behavioural approach
Number of subjects: 236
Study 20178056 — intervention group
Group type: COMPARATOR
Intervention: Common orthopaedic rehabilitation
Number of subjects: 236
Study 17118998 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg TAK-677 BID (n = 21)
Number of subjects: 65
Study 17118998 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg TAK-677 BID (n = 22)
Number of subjects: 65
Study 17118998 — intervention group
Group type: COMPARATOR
Intervention: Placebo BID (n = 22)
Number of subjects: 65
Study 16236684 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 32
Study 16236684 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 32
Study 16236684 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 32
Study 16236684 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane and Isoflurane
Number of subjects: 32
Study 12837043 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthalin
Number of subjects: 21
Study 12837043 — intervention group
Group type: EXPERIMENTAL
Intervention: Salomol
Number of subjects: 21
Study 12837043 — intervention group
Group type: COMPARATOR
Intervention: Ventolin
Number of subjects: 21
Study 9694052 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels in SpA patients
Number of subjects: 25
Study 9694052 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study 9694052 — intervention group
Group type: COMPARATOR
Intervention: Patients with rheumatoid arthritis (RA)
Number of subjects: 25
Study 9694052 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of sICAM‐1 with inflammatory parameters in SpA
Number of subjects: 25
Study 9694052 — intervention group
Group type: COMPARATOR
Intervention: Correlation of sICAM‐1 with inflammatory parameters in RA
Number of subjects: 25
Study 8081529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release magnesium chloride (Slo-Mag), 384 mg/d
Number of subjects: 28
Study 8081529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2596748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical extraoral force
Number of subjects: 200
Study 2596748 — intervention group
Group type: EXPERIMENTAL
Intervention: Combi extraoral force
Number of subjects: 200
Study 2596748 — intervention group
Group type: COMPARATOR
Intervention: No-headgear
Number of subjects: 200
Study 4552591 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug (bethanidine, debrisoquine, guanethidine)
Number of subjects: 137
Study 4552591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 30880108 — intervention group
Group type: EXPERIMENTAL
Intervention: iStent inject implantation (Model G2‐M‐IS)
Number of subjects: 505
Study 30880108 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery alone (control group)
Number of subjects: 505
Study 28968163 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus a nonsteroidal aromatase inhibitor (150 mg twice daily continuous schedule)
Number of subjects: 493
Study 28968163 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus a nonsteroidal aromatase inhibitor
Number of subjects: 493
Study 28968163 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 493
Study 26459346 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback training
Number of subjects: 41
Study 26459346 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 41
Study 24139456 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral internal jugular vein sheaths
Number of subjects: 117
Study 24139456 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous superior vena cava cannula
Number of subjects: 117
Study 22975340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue vaccine (3 injections at months 0, 6, and 12)
Number of subjects: 4002
Study 22975340 — intervention group
Group type: COMPARATOR
Intervention: Control (rabies vaccine or placebo)
Number of subjects: 4002
Study 19776293 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX899
Number of subjects: 8
Study 19776293 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX989
Number of subjects: 8
Study 19776293 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX899 and IDX989
Number of subjects: 8
Study 17261206 — intervention group
Group type: EXPERIMENTAL
Intervention: Active impedance threshold device
Number of subjects: 19
Study 17261206 — intervention group
Group type: COMPARATOR
Intervention: Sham impedance threshold device
Number of subjects: 19
Study 15111749 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.15%
Number of subjects: 80
Study 15111749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 11174492 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 1400
Study 10449888 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan (80 mg/160 mg q.d.)
Number of subjects: 69
Study 10449888 — intervention group
Group type: COMPARATOR
Intervention: atenolol (50 mg/100 mg q.d.)
Number of subjects: 69
Study 7869205 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 200 units/kg per day
Number of subjects: 20
Study 7869205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2218713 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior distraction using pedicle instrumentation (AO fixateur interne)
Number of subjects: 40
Study 2218713 — intervention group
Group type: COMPARATOR
Intervention: Anterior decompression and instrumentation (Kostuik‐Harrington device)
Number of subjects: 40
Study 2218713 — intervention group
Group type: COMPARATOR
Intervention: Anterior surgery
Number of subjects: 40
Study 2218713 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior surgery
Number of subjects: 40
Study 577626 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase ('Kabikinase') followed by oral anticoagulant therapy
Number of subjects: 26
Study 577626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod ('Arvin') for 6 days followed by oral anticoagulant therapy
Number of subjects: 26
Study 577626 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral anticoagulant therapy only)
Number of subjects: 26
Study 577626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod treatment
Number of subjects: 26
Study 577626 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase and ancrod treatments
Number of subjects: 26
Study 30956267 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg/day
Number of subjects: 217
Study 30956267 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol 20 mg/day
Number of subjects: 217
Study 28253389 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-induced sleep endoscopy with polygraphic monitoring (DISE-PG)
Number of subjects: 50
Study 25888774 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF‐BB/β‐TCP (Augment®)
Number of subjects: 40
Study 25888774 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and external fixation alone
Number of subjects: 40
Study 24010992 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg sublingual nitroglycerin tablet
Number of subjects: 420
Study 24010992 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg sublingual nitroglycerin tablet
Number of subjects: 420
Study 24010992 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tablet of isosorbide mononitrate
Number of subjects: 420
Study 24010992 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg nitroglycerin transdermal patch (used for 8 h)
Number of subjects: 420
Study 24010992 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of nitroglycerin ointment
Number of subjects: 420
Study 21293309 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 80 mg/day
Number of subjects: 16
Study 21293309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19298581 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily for 6 months
Number of subjects: 2766
Study 19298581 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 20 mg once daily for 6 months
Number of subjects: 2766
Study 18257347 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat electroacupuncture instrument with Chinese herb iontophoresis, combined with Meloxicam, Salazosulfamide, and Methotrexate
Number of subjects: 96
Study 18257347 — intervention group
Group type: COMPARATOR
Intervention: Simple western medicine
Number of subjects: 96
Study 15134122 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention messages disseminated through community popular opinion leaders (CPOLs); specific details on dosage and duration not available.
Number of subjects: 100
Study 11483788 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily antiinflammatory medications (mostly cromolyn sodium)
Number of subjects: 219
Study 11483788 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe persistent asthma
Number of subjects: 219
Study 11483788 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily antiinflammatory medications
Number of subjects: 219
Study 11483788 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality asthma home management measures
Number of subjects: 219
Study 9891542 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-drug regimens
Number of subjects: 2100
Study 9891542 — intervention group
Group type: COMPARATOR
Intervention: Single agent treatment (usually BCNU)
Number of subjects: 2100
Study 1284158 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg t.i.d. (days 8-14)
Number of subjects: 25
Study 6531964 — intervention group
Group type: EXPERIMENTAL
Intervention: Suckling mouse brain vaccine (SMBV)
Number of subjects: 136
Study 6531964 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal bovine kidney vaccine (FBKV) administered subcutaneously
Number of subjects: 136
Study 6531964 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal bovine kidney vaccine (FBKV) administered intramuscularly
Number of subjects: 136
Study 30095354 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT-A) injection plus rehabilitation therapy
Number of subjects: 30
Study 30095354 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation therapy alone
Number of subjects: 30
Study 30089525 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation with supervised exercise for 12 weeks, three times a week.
Number of subjects: 0
Study 30089525 — intervention group
Group type: COMPARATOR
Intervention: Placebo with supervised exercise for 12 weeks, three times a week.
Number of subjects: 0
Study 26963844 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (3600 mg daily)
Number of subjects: 108
Study 26963844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 25386212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and 2% lidocaine with 1:80000 epinephrine
Number of subjects: 61
Study 25386212 — intervention group
Group type: COMPARATOR
Intervention: Normal saline and 2% lidocaine with 1:80000 epinephrine
Number of subjects: 61
Study 23084383 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment for retinopathy of prematurity (ROP)
Number of subjects: 718
Study 23084383 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 718
Study 19342934 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-endoscopic interlaminar and transforaminal technique
Number of subjects: 87
Study 19342934 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical technique
Number of subjects: 87
Study 17438101 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b therapy
Number of subjects: 179
Study 17438101 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (healthy controls)
Number of subjects: 179
Study 17438101 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (proinflammatory cytokines levels)
Number of subjects: 179
Study 17438101 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian Network algorithm classification
Number of subjects: 179
Study 15185127 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP repair (n = 40)
Number of subjects: 80
Study 15185127 — intervention group
Group type: COMPARATOR
Intervention: PPOR (n = 40)
Number of subjects: 80
Study 15185127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TEP and PPOR
Number of subjects: 80
Study 11451596 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/day rhGH during hospitalization
Number of subjects: 38
Study 11451596 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhGH)
Number of subjects: 38
Study 10806764 — intervention group
Group type: EXPERIMENTAL
Intervention: Nao Yi-an granule (Chinese medicine group, CMG)
Number of subjects: 40
Study 10806764 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (western medicine group, WMG)
Number of subjects: 40
Study 7633009 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 18
Study 7633009 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% placebo
Number of subjects: 18
Study 2575983 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol 200mg once daily
Number of subjects: 529
Study 2575983 — intervention group
Group type: COMPARATOR
Intervention: nifedipine 20mg twice daily
Number of subjects: 529
Study 386045 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 386045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0